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Summary
DNA methylation was described almost a century ago. However, the rules governing its
establishment and maintenance remain elusive. Here, we present data demonstrating that active
transcription regulates levels of genomic methylation. We identified a novel RNA arising from the
CEBPA gene locus critical in regulating the local DNA methylation profile. This RNA binds to
DNMT1 and prevents CEBPA gene locus methylation. Deep sequencing of transcripts associated
with DNMT1 combined with genome-scale methylation and expression profiling extended the
generality of this finding to numerous gene loci. Collectively, these results delineate the nature of
DNMT1-RNA interactions and suggest strategies for gene selective demethylation of therapeutic
targets in disease.
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tIntroduction
DNA methylation is a key epigenetic signature implicated in transcriptional regulation,
genomic imprinting, and silencing of repetitive DNA elements1–2 and it occurs
predominantly within CpG dinucleotides. CpG dinucleotides are underrepresented in the
mammalian genome (~1%) and tend to cluster within CpG islands located in the vicinity of
the transcription start sites (TSSs) of the majority (~70%) of human protein-coding genes3.
While the bulk of genome is methylated at 70–80% of its CpGs, CpG islands are mostly
unmethylated in somatic cells3–4. This modification is mediated by the members of the DNA
methyltransferases (DNMTs) family conventionally classified as de novo (DNMT3a-b) and
maintenance (DNMT1). In terms of epigenetic inheritance, DNMT1 has the unique ability
to identify the hemimethylated portion of newly replicated DNA. This feature may explain
how DNMT1-mediated methylation could be an epigenetic mechanism maintaining the
status quo. However, it certainly does not explain how DNA methylation is altered,
particularly in disease states.
To examine how transcription may regulate the levels of genomic methylation, we
investigated methylation dynamics of the well-studied methylation-sensitive gene
CEBPA5–7, including the potential involvement of noncoding (nc) RNAs originating within
CEBPA locus. Recent discoveries of functional ncRNAs have provided new regulatory clues
to the control of epigenetic marks. Particularly, long ncRNAs (lncRNAs) have been shown
to regulate gene expression by interacting with chromatin modifiers, modulating
transcription factor activity and competing for miRNA binding8–16. One unexplored aspect
of regulation of gene locus DNA methylation was the possible involvement of transcripts
encoded within the region.
We identified a functional RNA arising from the CEBPA locus (ecCEBPA) that regulates
CEBPA methylation. This RNA interacts with DNMT1, resulting in prevention of CEBPA
gene methylation and robust CEBPA mRNA production. We show that such functional
DNMT1-RNA association occurs in numerous gene loci. We thus propose a novel
regulatory mechanism of gene methylation governed by RNAs.
Results
Characterization of ecCEBPA
Noncoding transcripts arising from the promoter and the downstream regions of coding
genes can affect expression of the corresponding genes17–19. We searched and identified
transcripts upstream and downstream of the intronless CEBPA gene. Strand specific RT-
PCR (data not shown) and Northern blot analysis of RNAs from four leukemic cell lines,
probing the region immediately after the CEBPA polyadenylation site, revealed the presence
of a major band of ~4.5 kb in HL-60 and U937 (where CEPBA is expressed), but not in
K562 or Jurkat cell lines (where CEBPA is expressed at low or undetectable levels) (Fig. 1a,
b). The identified transcript is distinct from the ~2.6 kb signal, detected with a CEBPA
coding region probe, and correlates with CEBPA mRNA expression. Unlike polyadenylated
CEBPA mRNA (Fig. 1c), this non-polyadenylated transcript is enriched in the nuclear
fraction (Supplementary Fig. 1a, b) suggesting functional roles independent of protein
coding potential.
We termed this nuclear non-polyadenylated CEBPA ncRNA “extra-coding (ec) CEBPA”,
since it does encompass the entire mRNA sequence in the same-sense orientation (shown by
primer extension and 5′3′RACE; Supplementary Information (SI); Supplementary Fig. 1c,
d). qRT-PCR analysis confirmed concordant expression between extra-coding and coding
transcripts, in both cellular and nuclear RNAs (Fig. 1d, e). Similar correlation was observed
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tin all tested human tissues (Supplementary Fig. 1e). Importantly, ecCEBPA synthesis
precedes the expression of its overlapping mRNA in the S phase (SI and Supplementary Fig.
1f, g) and is regulated by both RNA polymerase II and III (RNAP II and III; SI and
Supplementary Fig. h–p) as described for other loci20–22.
ecCEBPA inhibits DNA methylation and facilitates CEBPA expression
To examine the functional role of ecCEBPA in regulation of CEBPA transcription, we
performed both loss and gain-of-function experiments. Knock-down of ecCEBPA in U937
cell line (up to a 4-fold decrease) achieved by small hairpin (sh) RNAs targeting ecCEBPA
(but not CEBPA mRNA) led to a decrease of CEBPA mRNA expression of similar
magnitude (Fig. 2a, b), suggesting that ecCEBPA may regulate CEBPA expression.
Silencing of the CEBPA gene can be associated with DNA methylation of the
promoter6–7,23. To examine if there was a connection between ecCEBPA and methylation of
the CEBPA locus, we analyzed methylation within the distal promoter (located at −0.8–0.6
kb from the CEBPA TSS; Fig. 2a). Intriguingly, ecCEBPA knockdown led to a significant
increase in DNA methylation compared to the non-targeting control (Fig. 2c; Supplementary
Fig. 2a).
To investigate whether enforced expression of the ecCEBPA was sufficient to inhibit DNA
methylation, the downstream region of the ecCEBPA (R1; Fig. 2a) was overexpressed in
K562 cells expressing ecCEBPA and CEBPA mRNA at low to undetectable levels (Fig. 1b,
d). Overexpression of only part of the ecCEBPA was dictated by the necessity to distinguish
the methylation pattern of the endogenous CEBPA locus from that of the ectopically
expressed construct.
Ectopic expression of the ecCEBPA (R1) resulted in greater than 3-fold increase in mRNA
expression (Fig. 2d) whereas overexpression of an unrelated region (UR; located 45 kb
downstream) and regions immediately outside the ecCEBPA boundaries did not affect
mRNA levels (Supplementary Fig. 2b–d). Moreover, concomitant decrease of DNA
methylation in three tested regions within the CEBPA gene, distal promoter, coding region,
and 3′UTR, accompanied overexpression of ecCEBPA but not of the UR (Fig. 2e;
Supplementary Fig. 2e, f). Interestingly, comparative analysis of DNA methylation changes
imposed by ecCEBPA overexpression versus the hypomethylating agent 5′-Azacytidine (5-
Aza-CR), together with genome-scale analysis (reduced representation bisulfite sequencing,
RRBS24) of DNA methylation changes imposed by ecCEBPA versus UR overexpression,
revealed that ecCEBPA-mediated demethylation was relatively selective to the CEBPA locus
(Supplementary Fig. 2g–l). Indeed, increased mRNA expression and changes in methylation
status within the loci of the neighboring CEBPG and distant TP73 (on chr1p36) genes were
achieved after 5-Aza-CR treatment but not after ecCEBPA overexpression (Supplementary
Fig. 2g–k). Furthermore, RRBS analysis of promoter and 1st exon regions revealed that only
~3.3% of the interrogated loci (396 out of 11844) were hypomethylated at levels similar to
the CEBPA locus (Supplementary Fig. 2l).
Furthermore, ecCEBPA downregulation by the universal RNAPs inhibitor Actynomicin D
and RNAPIII-specific inhibitor ML-60218 (Supplementary Fig. 2m) led to a corresponding
increase in methylation of the CEBPA locus, in synchronized and unsynchronized U937cells
(Fig. 2f, g; Supplementary Fig. 2n). Despite comparable decreases in ecCEBPA levels in
both synchronized and unsynchronized cells (Fig. 2f), DNA methylation increase was more
prominent in synchronized cells (Fig. 2g), suggesting a cell cycle-specific action of the
ecCEBPA. Similar effect was observed in ML-60218-treated HL-60 cells (Supplementary
Fig. 1i; Supplementary Fig. 2o).
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tConsistently, we observed an inverse correlation between the CEBPA gene locus
methylation and the levels of ecCEBPA in HL-60, U937 and K562 cell lines (Supplementary
Fig. 2p).
Collectively, these data highlight the regulatory role of the ecCEBPA in CEBPA gene locus
methylation, most prominently during the S phase.
DNMT1 binds to RNA with greater affinity than to DNA
The changes in CEBPA methylation mediated by ecCEBPA prompted us to try to unveil the
mechanism through which it is achieved. Among DNMTs, DNMT1 is the one whose
expression and enzymatic activity peaks during S phase25. Increased ecCEBPA expression
occurs during the S phase (Supplementary Fig. 1g), whereas inhibition of ecCEBPA during
S phase results in a substantial increase of CEBPA locus DNA methylation (Fig. 2f, g,
Supplementary Fig. 2n). We therefore asked whether the presence of ecCEBPA during S
phase led to RNA interference of DNMT1 activity.
To determine if DNMT1 physically associates with ecCEBPA we performed RNA
Immunoprecipitation (RIP) with specific anti-DNMT1 antibody (Supplementary Fig. 3a).
We observed ecCEBPA enrichment in DNMT1-RNA precipitates, demonstrating a physical
interaction between ecCEBPA and DNMT1 (Fig. 3a, b; Supplementary Fig. 3a). Analysis of
polyA(+)/(−) fractions in DNMT1-RNA precipitates revealed enrichment of CEBPA
transcripts in the polyA(−) fraction (Supplementary Fig. 3b, c), suggesting that the major
component of CEBPA transcripts in DNMT1-RNA precipitates was ecCEBPA.
To investigate the molecular properties of RNA-DNMT1 interaction in vitro, we performed
RNA electrophoresis mobility shift assays (REMSA). RNA oligonucleotides corresponding
to the 5′ and 3′ parts of the ecCEBPA were selected by: (i) ability (R2, R5 and R6) and
inability (R4) to fold into stem-loop structures26; (ii) presence (R2, R5 and R6) or absence
(R4) of CpG dinucleotides (Fig. 3a). RNA-DNMT1 complex formation was observed with
all RNA oligonucleotides able to fold into stem-loop structures (Fig. 3c–e). Unlike DNA27,
CpG UpG substitutions, neutral with regard of secondary structures, did not affect binding
(mutR2; Fig. 3c). In contrast, mutations abrogating RNA folding ability affected RNA-
DNMT1 binding (mut R5; Fig. 3e). Analyses extended to a number of RNA
oligonucleotides not related to the ecCEBPA (single stranded [ss] R1 and R3; and double
stranded [ds] R13; Supplementary Fig. 3d), confirmed DNMT1 binding to stem-loop
structured RNAs (SI and Supplementary Fig. 3e–f). Importantly, REMSA performed in
presence of increasing concentrations of spermine, a molecule with four positive charges at
high density, excluded a case of charge-charge interactions (Supplementary Fig. 3g),
supporting a strong element of structural recognition between DNMT1 and RNA
To determine the relative affinity of DNMT1 for ecCEBPA versus DNA, ssRNA
oligonucleotides capable of forming secondary structures (R5) and corresponding
unmethylated (umDNA; D5/D6), hemimethylated (hmDNA; D5/D6), and fully methylated
(mDNA; D5/D6) dsDNA (Fig. 3a), at a constant molar concentration, were titrated with
increasing range of DNMT1 enzyme concentrations using EMSA. RNA formed complexes
beginning at <0.013 μM DNMT1, whereas DNA at >0.026 μM DNMT1 (Fig. 3f), with a
mean dissociation constant (Kd) for RNA of 0.045μM and between 0.082 and 0.14μM for
DNA, indicating that RNA has a stronger affinity for the enzyme than DNA (Fig. 3f).
Consistently, RNA unable to fold into stem-loop structures (R4; Fig. 3g) did not display the
same affinity for DNMT1 as “folded” RNA (R5; Fig. 3f, g), demonstrating that RNA
secondary structure represents an essential feature of RNA-DNMT1 complex formation.
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tFinally, to assess DNMT1 domain required for the RNA binding, DNMT1-GST-purified
domains (Fig. 3h) were incubated with RNA oligonucleotides able or unable to fold into
stem-loop structures, R5 and R4, respectively (Fig. 3e, g). The catalytic domain, including
the Target Recognition Domain (TRD)28, shared by both fragments F4 and F5, selectively
bound the “folded” RNA oligonucleotide (Fig. 3h). Next, we deleted the DNMT1 region
including the sequence overlapping F4 and F5. Unfortunately, even minimal removal of the
TRD led to disruption of DNMT1 enzymatic activity (data not shown) making further
refinement of the binding domain not feasible.
Collectively, these data indicate that RNA can associate with DNMT1. This interaction is
not contingent upon the presence of CpG dinucleotides, is not a trivial ion pairing, and is
dependent upon certain RNA secondary structures features. Importantly, DNMT1, via its
catalytic domain, binds with higher affinity to folded RNA than to DNA.
Transcription interferes with DNMT1 methylation of DNA
To examine whether newly synthesized transcripts could interfere with the ability of
DNMT1 to methylate hmDNA, we performed a combined in vitro transcription-DNA
methylation assay. A hmDNA segment (bottom strand methylated) was engineered
downstream of the T7 RNA polymerase promoter (Supplementary Fig. 4a–h), and DNMT1
methylase activity was monitored in presence and absence of transcription (Fig. 4a–d). In
the absence of polymerase, there was, as expected, increased DNA methylation of the upper
strand (Fig. 4d–f; Supplementary Fig. 4i–j). In contrast, no changes in DNA methylation
were observed in the presence of both polymerases and DNMT1 (Fig. 4c–f and
Supplementary Fig. 4i–j). Standard in vitro DNA methylation assays confirmed the
enzymatic impairment of DNMT1 mediated by ribooligonucleotides (Fig. 4g). Similarly, T7
RNA polymerase29-induced transcription in living cells led to a pronounced decrease in
DNA methylation (SI and Supplementary Fig. 4k–p).
Thus, RNA can complex with and impact DNMT enzymatic activity in vitro30–32 and in
living cells. These findings suggest that RNAs arising from methylation-sensitive genes and
their promoters can regulate expression of the corresponding genes by interfering with DNA
methylation.
RNA inhibition of DNA methylation is a global effect
Our observations suggested an inverse correlation between RNA-DNMT1 complexes and
methylation of the CEBPA locus. Therefore, we sought to explore the extent of DNMT1-
RNA association in other genomic loci with respect to DNA methylation and gene
expression profiles. cDNA libraries made of RNAs co-immunoprecipitated with anti-
DNMT1 antibody (DNMT1 library) and IgG (control library) were tested for ecCEBPA
enrichment (“quality control”; Supplementary Fig. 5a) and subsequently analyzed by
massively parallel sequencing11. Using 76-base paired-end sequencing, we produced a total
of 30.25 and 26.95 million pair reads for DNMT1 and control libraries, respectively
(detailed analysis described in Methods). All significant DNMT1 peaks (a total of 16,186;
P<0.0001; false discovery rate of 7.5%) were annotated with CEAS33 build on RefSeq hg19
(Supplementary Fig. 5b). All DNMT1 peaks were also annotated using the known RNAs
databases provided by HOMER34 (Supplementary Fig. 5c). We focused on genomic regions
encompassing the 3 kb upstream to the TSS and downstream to the transcription ending site
(TES) of the annotated genes, referred to as “gene loci”. We identified 6,042 gene loci
containing one or more peaks from the DNMT1 library (Methods: Data integration).
To confirm that DNMT1 RIP-Seq peaks were associated with actual transcribed elements,
RNA-Seq was conducted on polyA (−) HL-60 RNA. 375 million 76-bp paired-end reads
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twere aligned to hg19 using TopHat235 and assembled using cufflinks36. 14,077 (87.02%) of
specific DNMT1 peaks overlapped with a transcribed element from the RNA-Seq assembly
of the polyA (−) HL-60 RNA fraction. Thus, a vast majority of DNMT1-interacting-RNAs
(DiRs) were not polyadenylated.
Additionally, we performed a similar analysis with total HL-60 RNA (300 million 76-bp
paired-end reads). 14,497 specific DNMT1 peaks (89.61%) were found to overlap with
transcripts from the total HL-60 RNA-Seq assembly. A merged assembly of the two RNA
libraries validated a total of 15,238 (94.20%) DNMT1 RIP-Seq peaks (Fig. 5a). These
findings confirmed the existence of DiRs on a genome-wide level. Next, we assessed the
linkage between genomic loci giving rise to DiRs, levels of genomic methylation by
RRBS24 and expression of the corresponding nearby genes by microarray analysis,
performed on HL-60 cells. Within all 15,806 RRBS-covered loci, 10,973 loci were not
covered by DNMT1 specific peaks (DNMT1-unbound group) and 4,833 loci were covered
by DNMT1 specific peaks (DNMT1-bound group). These 4,833 loci represent the majority
(79.99%) of all 6,042 gene loci identified by DNMT1 RIP-Seq (Supplementary Fig. 5d).
Within DNMT1-bound and unbound groups, genes were stratified according to expression
and methylation levels (the latter computed as the mean of all CpG β-scores from -2 kb from
the TSS to the end of the first intron). A negative correlation between DNMT1-RNA
association with gene locus methylation status was observed (Supplementary Fig. 5e).
Next, we clustered genes within both groups according to levels of expression and
methylation. We defined genes as: “expressed” or “low or not expressed” if the log2 score
was above or below 4, respectively; and “hypomethylated” or “methylated” if the mean of
all CpG scores was below or above 50%, respectively (Methods: RRBS-Data integration).
This approach allowed us to identify four clusters within DNMT1-unbound, DNMT1-
bound, and all RRBS-covered groups (Fig. 5b). Hypomethylated and expressed genes
appeared to be predominant in the DNMT1-bound group (cluster C), accounting for 56.64%;
whereas hypermethylated and low or unexpressed genes represented the 51.45% in the
DNMT1-unbound group (cluster B). Moreover, the numbers of genes in clusters B (5646
genes) and C (2737) were significantly higher than numbers of genes in clusters A, F, E
(2528, 1653, 1146) and G, H, D (584, 930, 582), respectively (P-value <0.0001). Examples
of genes from clusters B and C are presented in Fig. 5c and Supplementary Fig. 5f–h).
Further, genes from cluster C belonged to a multiplicity of biological processes, indicating
the diversity of DiRs (Supplementary Fig. 6a). Interestingly, ~60% of these biological
process gene ontology (BP-GO) terms (pvalue <= 0.01) were shared with pyknons-related
BP-GO37. This overlap is 71 fold higher than expected. Moreover, among all DNMT1 RIP-
seq peaks, 46% carry at least one pyknon (Supplementary Fig. 6b) suggesting a potential
relation between DiRs and pyknons.
Grouping of genes in clusters A, F, E, G, H, and D could result from technical limitations of
RRBS, contingent upon the genomic location of the restriction sites and the DNA library
size-selection38, or these genes may be governed by yet another mechanism of
transcriptional control.
In conclusion, we have generated the first comprehensive map cross-referencing DiRs to
DNA methylation and gene expression. These data demonstrate that RNA-
DNMT1association is widespread and might modulate genomic DNA methylation (Fig. 5d).
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This study explores the role of a new class of RNAs: DNMT1-interacting RNAs. Using the
CEBPA gene as a model, we show that mRNA transcription is accompanied by the
production of an additional RNA species, ecCEBPA. In every instance studied, DNA
methylation levels are inversely correlated with ecCEBPA levels, and the extent of DNA
methylation is determined by the absence or presence of ecCEBPA (Fig. 2).
We demonstrate that ecCEBPA associates with DNMT1 and establish a functional link
between ecCEBPA and CEBPA expression as through RNA-DNMT1 association.
We show that RNAs capable of adopting stem-loop structures exhibit the potential to
associate with DNMT1, suggesting that the basis of this preferential interaction is
recognition of RNA secondary structure (Fig. 3).
Importantly, we demonstrate that this type of RNA-DNMT1 association is not restricted to
the CEBPA gene locus. We have globally identified RNA species associated with DNMT1
and their relationship to DNA methylation and gene expression. These alignments defined a
large set of expressed unmethylated genes and a complementary set of silent methylated
genes that could possibly be induced following expression of the DiR.
Our findings suggest a model of site specific DNMT1 sequestration in which RNAs act as a
shield, halting DNMT1 and thus modulating DNA genomic methylation at their site of
transcription (Fig. 5d). Indeed, the loss of CEBPA locus methylation following
overexpression of the ecCEBPA does not support a model of trivial titration (‘squelching’39)
of DNMT1 but suggests a cis regulatory role of the DiR. We propose a model wherein
RNAs contain a locus-selective triplex/quadruplex40 forming part, the ‘anchor’, mooring the
DNMT1-RNA complex to the locus, and a DNMT1-interacting part, the ‘bait’, stem loop-
like forming sequence serving to lure the DNMT1 into association. DNMT1 sequestration
by RNA does resemble a competing mechanism described for other regulatory RNAs, e.g.,
competing endogenous RNAs (ceRNAs)15–16,41. However, unlike ceRNAs, the ecCEBPA
model also introduces the requirements for both functional and physical co-
compartmentalization of the RNA, its parental locus, and DNMT1. Given the DiR’s ability
to bind DNMT1, it is tempting to hypothesize that DiRs represent a novel class of RNA
regulons42.
Taken together, these data support the hypothesis that RNA participates in the establishment
of genomic methylation patterns by interacting with DNMT1 and pave the way for the site-
specific adjustments of aberrant DNA methylation.
METHODS
Cell Culture
All cell lines were obtained from ATCC and grown according to the manufacturer’s
instructions in the absence of antibiotics. The DNMT1 hypomorphic cell line HCT116 hypo
and wild type counterpart HCT116 were grown in McCoy’s 5A modified medium
supplemented with 10% FCS.
RNA isolation and Northern Blot Analysis
Total RNA isolation, electrophoresis, transfer, and hybridization were carried out as
described49. Cytoplasmic RNA was isolated with the Paris kit (Ambion) according to the
manufacturer’s recommendations. Preparation of nuclear RNAs: we used a method derived
from protocols of nuclei isolation50, with minor modifications. Briefly, equal amounts of
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tviable cells (~50 million) were washed with ice-cold PBS supplemented with 5 mM vanadyl
complex, 1 mM PMSF and resuspended in the ice-cold lysis buffer: 1x Buffer A (10 mM
HEPES-NaOH pH 7.6; 25 mM KCl; 0.15 mM spermine; 0.5 mM spermidine; 1 mM EDTA;
2 mM Na butyrate); 1.25 M sucrose; 10% glycerol; 5 mg/mL BSA; 0.5% NP-40; freshly
supplemented with protease inhibitors (2 mM leupeptin, add as x400; 2 mM pepstatin, add
as x400; 100 mM benzamidine, add as x400; a protease inhibitor cocktail (Roche Applied
Science, Cat. No. 1836153), 1 tablet/375 μL H2O, add as x100; 100 mM PMSF, add as
x100); 2 mM vanadyl complex (New England Biolabs); and 20 units/mL RNase inhibitor
(RNAguard; Amersham Biosciences). Samples were incubated at 0°C for ~10 minutes and
passed through numerous 40 up and down strokes in a Dounce homogenizer (10 with pestle
A and 30 with pestle B). The pelleted nuclei were resuspended in 0.5 ml lysis buffer and
diluted with 2.25 mL Dilution Buffer (2.13 mL “Cushion” buffer plus 0.12 mL 0.1 g/mL
BSA), freshly supplemented with protease inhibitors and overlaid onto 2 mL “cushions”
(200 mL “Cushion” buffer consists of 15 mL ddH2O; 15 mL 20x Buffer A; 30 mL glycerol;
240 mL 2.5 M sucrose; freshly supplemented with protease inhibitors) into one SW 55 Ti
tube and centrifuged at 24,400 rpm, 60 minutes, 4°C. The pelleted nuclei were resuspended
in 1 mL Storage buffer (1.75 mL ddH2O; 2 mL glycerol; 0.2 mL 20x Buffer A), freshly
supplemented with protease inhibitors. Nuclear RNAs were extracted as described50. All
total, cytoplasmic and nuclear RNA samples used in this study were treated with DNase I
(10 U of DNase I per 3 μg of total RNA; 37°C for one hour; in the presence of RNase
inhibitor). After DNase I treatment, RNA samples were extracted with acidic phenol (pH
4.3) to eliminate any remaining traces of DNA. Polyadenylated and non-polyadenylated
RNA fractions were selected with the MicroPoly(A)Purist™ purification kit (Ambion).
cDNA syntheses were performed with Random Primers (Invitrogen) with Transcriptor
Reverse Transcriptase (Roche Applied Science) according to the manufacturer’s
recommendation. cDNA was purified with a High Pure PCR Product Purification Kit
(Roche Applied Science).
qRT-PCR
SYBR green reactions were performed using iQ Sybr Green supermix (Biorad; Hercules,
CA); PCR conditions: 95°C (10 min), followed by 40 cycles of 95°C (15s) and 60°C (1min)
72°C (1min). TaqMan analysis was performed using Hotstart Probe One-step qRT-PCR
master mix (USB); PCR conditions: 50°C (10 min.), 95°C (2 min.), followed by 40 cycles of
95°C (15 sec.) and 60°C (60 sec.). Primers and probes are presented in Supplementary Data
1 (SI). qRT-PCR primer set for the CEBPA mRNA is located in the coding region (black
double-headed arrow Fig. 1a) and after the polyA signal for the ecCEBPA (white double-
headed arrow Fig. 1a).
Primer extension and 5′/3′ RACE
cDNA from the HL-60 cell line was synthesized as described above and run in alkaline
conditions51. Southern blot transfer and hybridization with oligonucleotide AL16 were
performed as previously reported51. Oligonucleotide sequences are shown in Supplementary
Data 1 (SI). 5′/3′ RACE was performed on two myeloid cell lines HL-60 and U937 using
the Exact START™ Eukaryotic mRNA 5′- & 3′-RACE Kit (Epicentre) according to the
manufacturer’s instructions. See Supplementary Data 1 (SI) for primer sequences.
Double Thymidine block (early S-phase block)
HL-60 cells were grown to 70–80% confluence, washed twice with 1xPBS and cultured in
DMEM (10% FCS) + 2.5 mM Thymidine for 18 h (first block). Thymidine was washed out
with 1xPBS and cells were grown in DMEM (10% FCS). After 8 hours cells were cultured
in presence of thymidine for 18 h (second block) and then released as described. Synchrony
Di Ruscio et al. Page 8
Nature. Author manuscript; available in PMC 2014 May 21.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
twas monitored by flow cytometry analysis (propidium iodide staining) using a LSRII flow
cytometer (BD Biosciences) at the Harvard Stem Cell Institute/Beth Israel Deaconess
Medical Center flow cytometry facility.
DRB, ML-60218, α-Amanitin and Actinomycin D treatment
After release from double thymidine block, HL-60 cells were treated with 100 μM 5,6-
Dichlorobenzimidazole 1-β–D-ribofuranoside52 (DRB) (Sigma Aldrich) for 1, 2, and 3
hours. HL-60 cells were treated with 12.5, 25, 50, or 100 μM ML-6021853–54
(Calbiochem®) for 24 hours. HL-60 cells were treated with 5, 23, 50, 75, 100, or 150 μg/mL
α-Amanitin (Sigma-Aldrich) for 14 hours. Synchronized and unsynchronized U937 cells
were treated with ML-60218 at 100 μM and Actinomycin D (Sigma-Aldrich) at 150 μM for
7 hours. Total RNA was harvested as described above and expression levels of CEBPA,
ecCEBPA, and 5S were measured by TaqMan qRT-PCR.
Nuclear Chromatin (ChIP) and RNA immunoprecipitation (RIP)
ChIP was performed as previously described19. Fold enrichment was calculated using the
formula 2 (−ΔΔCt [ChIP/NIS]). Antibodies used for ChIP are listed in Supplementary Table 1
(SI).
RIP was performed as described by Ebralidze et al.14. Day I: Cross-linked nuclei were
collected as following: 60×106 HL-60 cells were cross-linked with 1% formaldehyde
(formaldehyde solution, freshly made: 50 mM HEPES-KOH; 100 mM NaCl; 1 mM EDTA;
0.5 mM EGTA; 11% formaldehyde) for 10 minutes at room temperature. Crosslinking was
stopped by adding 1/10th volume of 2.66 M Glycine, kept for 5 minutes at room temperature
and 10 minutes on ice. Cell pellets were washed twice with ice-cold PBS (freshly
supplemented with 1 mM PMSF). Cell pellets were resuspended in cell lysis buffer (volume
= 4 mL): 1x Buffer (10 mM Tris pH 7.4; 10 mM NaCl; 0.5% NP-40, freshly supplemented
with protease inhibitors (protease inhibitors cocktail: Roche Applied Science, Cat. No.
1836153, 1 tablet/375 μL H2O; add as x100), 1 mM PMSF, and 2 mM vanadyl complex
(NEB). Cells were incubated at 0°C for 10–15 minutes and homogenized by Dounce (10
strokes pestle A and 40 strokes pestle B). Nuclei were recovered by centrifugation at 2,000
rpm for 10 minutes at 4°C. Nuclei were resuspended in 3 ml 1x Resuspension Buffer (50
mM HEPES-NaOH, pH 7.4; 10 mM MgCl2) supplemented with 1 mM PMSF and 2 mM
vanadyl complex. DNase treatment (250 U/ml) was performed for 30 minutes at 37°C, and
EDTA (final concentration 20 mM) was added to stop the reaction. Resuspended nuclei
were sonicated once for 20s (1 pulse every 3 seconds) at 30% amplitude (Branson Digital
Sonifer, Danbury, CT). Immunoprecipitation for RIP was performed as follows: Before
preclearing, the sample was adjusted to 1% Triton X-100; 0.1% sodium deoxycholate;
0.01% SDS; 140 mM NaCl; Protease inhibitors; 2 mM vanadyl complex; and 1 mM PMSF
to facilitate solubilization. Preclearing step: ~ 50 μL magnetic beads (Protein A or G
Magnetic Beads; #S1425S or #S1430S NEB) were added to the sample and incubation was
carried out for 1 h on a rocking platform at 4°C. Beads were removed in a magnetic field.
The sample was divided into three aliquots: (i) antibody of interest: either DNMT1 antibody
(Abcam, cat# ab87656) or anti-cap antibody (Anti-m3G-/m7G-cap; Synaptic Systems); (ii)
preimmune serum: IgG (Sigma-Aldrich); (iii) no antibody, no serum (input). 5 μg antibody
or preimmune serum was added to the respective aliquot and incubation performed on a
rocking platform overnight at 4°C. Input was stored at −20°C after addition of SDS to 2%
final concentration. Day II. 200 μL of Protein A coated super-paramagnetic beads (enough
to bind 8 μg IgG) were added to the samples and incubated on a rocking platform for 1 h at
4°C. Six washes were performed with immunoprecipitation buffer (150 mM NaCl; 10 mM
Tris-HCl, pH 7.4; 1 mM EDTA; 1 mM EGTA pH 8.0; 1% Triton X-100; 0.5% NP-40
freshly supplemented with 0. 2 mM vanadyl complex and 0.2 mM PMSF) in a magnetic
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tfield. Proteinase K treatment to release DNA/RNA into solution and to reverse HCHO
crosslinking was performed in 200 μL of: 100 mM Tris-HCl, pH 7.4; 0.5% SDS for the
immunoprecipitated samples and in parallel for the input; Proteinase K, 500 μg/ml at 56°C
overnight. Day III. Beads were removed in magnetic field. Phenol (pH 4.3) extraction was
performed after addition of NaCl (0.2 M final concentration). EtOH precipitation (in the
presence of glycogen); 3 hours at −20°C. The pellet was dissolved in 180 μL H2O, heated at
75 °C for 3 minutes, and immediately chilled on ice. Samples were treated with DNase I
(250 U/ml) in the presence of RNase inhibitor 300 U/ml in x1 buffer # 2 (NEB) at 37°C for
30 minutes. Phenol (pH 4.3) extraction and EtOH precipitation were repeated. 15. The RNA
pellet was dissolved in 50 μL H2O.
Tobacco Acid Pyrophosphatase (TAP), 5′-Phosphate-Dependent- Exonuclease
(Terminator) treatment
Equal amounts of RNA harvested from HL-60 cells (as described above) were digested with
TAP (Epicentre, Cat. # T81050), Terminator (Epicentre, Cat. # TER51020), or no enzyme
according to the manufacturer’s instructions. RNA was re-extracted in presence of Glycogen
(Ambion) with acidic phenol (pH 4.3), precipitated with Ethanol and resuspended in ddH2O.
ecCEBPA, CEBPA, and 18S expression levels were measured by qRT-PCR using the
TaqMan primer sets indicated in Supplementary Data 1 (SI).
Down-regulation of ecCEBPA
Three different short hairpin RNAs targeting human ecCEBPA and scrambled control were
designed according to Dharmacon software and cloned into the lentiviral vector pLKO.1
(Sigma Aldrich), which has a puromycin selection marker. shRNA sequences are shown in
Supplementary Data 1. Lentiviral particles were produced as previously described55.
HEK293T cells were co-transfected with either empty vector or the pLKO-shRNA vector
and Gag-Pol and Env constructs using Lipofectamine TM 2000 (Invitrogen) according to the
manufacturer’s recommendation. Virus containing supernatants were collected 48 and 72
hours after transfection and concentrated using a Centricon Plus-70 100000 MWCO column
(Millipore). Lentiviral transduction was performed in the presence of Hexadimethrine
bromide (final concentration 8 μg/ml) in the human myeloid cell line U937. Puromycin
(2μg/ml) was added to the cultures two days after infection. Resistant clones were selected
and screened for down-regulation of ecCEBPA by qRT-PCR.
Up-regulation of ecCEBPA
The 3′ ecCEBPA region (R1), the upstream (upR) and downstream (dwR) ecCEBPA
regions, and the unrelated genomic region (UR, see Supplementary Data 1) were cloned into
the pBabe retrovirus vector harboring a puromycin selection marker (Addgene; plasmid
1764). Oligonucleotide sequences used to amplify both regions are shown in Supplementary
Data 1. K562 cells were transfected with the Amaxa Cell Line Nucleofector® Kit V,
Program T-003. Puromycin (2 μg/ml) was added to the cultures 2 days after transfection.
Resistant clones were selected and screened for upregulation of ecCEBPA and the unrelated
region (UR) by Northern Blot Analysis.
Bisulfite Treatment, Combined Bisulfite Restriction Analysis Assay (COBRA) and Bisulfite
Sequencing
The methylation profile of the CEBPA gene locus was performed by bisulfite sequencing as
previously described56. Briefly, 1μg of genomic DNA was bisulfite converted by using the
EZ DNA Methylation kit (Zymo Research; Orange, CA). Primers and PCR conditions for
bisulfite sequencing and combined bisulfite restriction analysis assay (COBRA) are
summarized in Supplementary Data 1. For COBRA, PCR products were gel-purified and
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tincubated with BstUI at 60°C for 3 h. The digested DNA was then separated on a 3.5%
agarose gel and stained with ethidium bromide. For bisulfite sequencing, PCR products were
gel-purified (Qiagen) and cloned into the pGEM®-T Easy Vector System (Promega).
Sequencing results were analyzed using BiQ analyzer software57. Samples with conversion
rate <90% and sequences identity <70% as well as clonal variants were excluded from our
analysis55. The minimum number of clones for each sequenced condition was ≥ 6. Primer
sequences are shown in Supplementary Data 1 (SI).
5′ Azacytidine (5Aza-CR) treatment58
K562 cells were treated with 5Aza-CR (Sigma Aldrich) according to the manufacturer’s
instructions. Medium was refreshed every 48 hours. RNA (for RT-PCR) and genomic DNA
(for bisulfite sequencing) were isolated after 7 days of treatment.
MassARRAY
Quantitative DNA methylation analysis using the MassARRAY technique was performed
by Sequenom, Inc., as previously described43. Briefly, 1 μg of genomic DNA was converted
with sodium bisulfite using the EZ DNA methylation kit (Zymo Research, Orange,
California), PCR amplified, in vitro transcribed, and then cleaved by RNase A. The samples
were then quantitatively tested for their DNA methylation status using matrix-assisted laser
desorption ionization-time of flight mass spectrometry. The samples were desalted and
spotted on a 384-pad SpectroCHIP (Sequenom) using a MassARRAY nanodispenser
(Samsung), followed by spectral acquisition on a MassARRAY Analyzer Compact MALDI-
TOF MS (Sequenom). The resulting methylation calls were obtained using the EpiTyper
software v1.0 (Sequenom) to generate quantitative results for each CpG site or an aggregate
of multiple CpG sites. The methylation levels of aggregated multiple CpGs were calculated
as the mean of each CpGs methylation value and presented as percentage. Primer sequences
are provided in Supplementary Excel File 1.
Transfection of human DNMT1-HA tag construct and western blot analysis
The human DNMT1-HA tagged cloned into the expression vector pCDNA3.1 was a kind
gift from Prof. Steven Baylin. HEK293T cells were transfected using Lipofectamine 2000,
and 2 days later harvested for western blot analysis. Single cell suspensions were lysed with
modified RIPA buffer, and whole cell lysates separated on 6 % SDS-PAGE gels.
Immunoblots were stained with the following primary antibodies: DNMT1 (1:5000; Abcam,
cat# ab87656) and HSP90 (1:2000, BD Bioscience). All secondary antibodies were
horseradish peroxidase (HRP) conjugated (Santa Cruz) and diluted 1:5000 for rabbit-HRP,
and 1:3000 for mouse-HRP. Western Blot analysis for the HCT116 hypo and wild type cell
line was similarly performed.
T7 polymerase-induced transcription
The T7 expression system is based on technology developed at Brookhaven National
Laboratory under contract with the U.S. Department of Energy and is the subject of patents
and pending applications. Full information may be obtained from the Office of Intellectual
Property and Sponsored Research, Brookhaven National Laboratory, Upton, New York
11973, telephone 631-344-7134. Maps of T7 polymerase constructs are presented in Dunn et
al.,59. Briefly, the murine RAW 264.7 cell line was stably transfected with a construct
carrying the human genomic segment under T7 promoter control (derived from pBlueScript
plasmid; Agilent, USA). After selection in G418, individual clones were transfected with T7
polymerase-expressing mammalian constructs and were tested by COBRA for genomic
methylation.
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tElectrophoretic gel mobility shift assays (EMSAs) and Kd determination
DNA and RNA oligonucleotides (15 pmol) were end-labeled with [γ-32P] ATP (Perkin
Elmer) and T4 polynucleotide kinase (New England Biolabs). Reactions were incubated at
37°C for 1h and then passed through G-25 spin columns (GE Healthcare) according to the
manufacturer’s instructions to remove unincorporated radioactivity. Labeled samples were
gel-purified on 10% polyacrylamide gels. Binding reactions were carried out in 10 μL
volumes in the following buffer: 5 mM Tris pH 7.4, 5 mM MgCl2, 1 mM DTT, 3% v/v
glycerol, 100 mM NaCl. Various amounts (0.021–0.156 μM) of purified DNMT1 protein
(BPS Bioscience Inc.) were incubated with 1.1 nM of 32P-labeled dsDNA and ss/ds RNAs.
In the competitive assay, a fixed amount of protein and increasing amounts of competitors
(dsDNA or poly [dI-dC]) were used. All reactions were assembled on ice and incubated at
room temperature. Samples were separated on 6% native polyacrylamide gels (0.5xTBE; 4
°C; ~3h at 140 V). Gels were dried and exposed to X-ray film and/or PhosphoroImager
screens. Quantitation was done with ImageQuant software. For affinity assays, the percent
shifted species was determined as follows: the migration of the labeled DNA in this reaction
was defined as zero percent shifted and the ratio of the PhosphoroImager counts in the area
of the lane above this band to the total counts in the lane was defined as background and
subtracted from all other lanes. This band represented total input. Subsequent lanes
containing DNMT1-nucleic acid complexes were treated identically, and the percentage
complex formation was calculated as follows: [% bound complex = (1 − ((unbound −
background)/(Input − background))]. All experiments contained a control reaction lacking
DNMT1. The percentage complex formation was plotted as a function of DNMT1
concentration using non-linear regression analysis performed with Prism 4.0a software.
RNA and DNA oligonucleotides used in EMSA are shown in Figure 3a and Supplementary
Figure 3d and listed in Supplementary Data 1.
ecCEBPA binding to GST-DNMT1 fragments
GST and GST-DNMT1 fragments were expressed and purified by glutathione sepharose
affinity beads (GE Healthcare Life Sciences) as previously described60. Protein
concentrations for the recombinant GST and GST-DNMT1 fragments were determined by
gel electrophoresis and subsequent Coomassie staining and densitometry. 32P end-labeling
of ecCEBPA oligonucleotides was carried out at 37°C for 30 min in a total volume of 50 μl.
The reaction contained 50 pmoles of ecCEBPA, adenosine 5′-Triphosphate, [γ-32P] (specific
activity 3000 Ci/mmol, Perkin Elmer), and 20 units of T4 kinase (New England Biolabs)
mixed in assay buffer (70 mM Tris-HCl, 10 mM MgCl2, 5 mM Dithiothreitol, pH 7.6). The
labeled ecCEBPA-32P was purified with illustraMicroSpin G-25 Columns (GE Healthcare
Life Sciences) according to manufacturer’s specifications. Equal amounts of the GST and
GST-DNMT1 fragments were mixed with 5μl ecCEBPA-32P, in duplicate, and incubated at
37°C for 10 min in a total volume of 25 μL of reaction buffer (50 mM Tris-HCl, 1 mM
Dithiothreitol, 1 mM EDTA, 5 % Glycerol, pH 7.8). The sepharose beads were then washed
4 times in phosphate buffered solution and placed in 3 ml of scintillation fluid and
bound 32P was measured for 1 minute. All measurements were normalized to 32P readings
for the corresponding input 32P-ecCEBPA.
in vitro Transcription-Methylation Assay in vitro
transcription-methylation assays were performed on hemimethylated DNA (hmDNA;
described in Supplementary Information, legend to Supplementary Figure 4) in the presence
or absence of 5 U of human DNMT1 enzyme (New England Biolabs) and 5 U of T7 RNA
polymerase (Promega) or 5 U of E. coli RNA polymerase sigma-saturated holoenzyme
(Epicentre). Reactions were performed in DNMT1 buffer according to the manufacturer’s
recommendations supplemented with rNTPs and 1.25 mM MgCl2, including the “DNMT1
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tonly” reaction. This pre-determined concentration of Mg2+ cations is high enough to sustain
activity of RNA polymerases and low enough not to inhibit DNMT1 activity.
DNMT1 in vitro methylation assay
DNMT1 enzymatic assays were carried out in duplicate at 37°C, for 30 min in a total
volume of 25 μL. The reaction contained S-adenosyl-L-[methyl-32H]methionine (AdoMet)
(specific activity 18 Ci/mmol, Perkin Elmer), 200ng of substrate DNA, recombinant
DNMT1 enzyme (25 pmoles), and ecCEBPA (25 pmoles) mixed in assay buffer (50 mM
Tris-HCl, 1 mM Dithiothreitol, 1 mM EDTA, 5 % Glycerol, pH 7.8). Methyltransferase
reactions were snap frozen in an ethanol-dry ice bath. The entire reaction volume (25 μl)
was spotted on 2.5 cm DE81 membranes (GE Healthcare, catalog no. 3658–325). These
membranes were processed by washes in 3×1 ml of 0.2 M ammonium bicarbonate, 3×1 ml
of water, and 3×1 ml of ethanol. Processed membranes were air-dried, placed in 3ml of
scintillation fluid and tritium incorporation was measured for 1 min. Background subtraction
(no DNA substrate) was performed for all experimental sample counts.
RNA Immunoprecipitation Sequencing (RIPseq)
Total RNA immunoprecipitated with DNMT1 antibody (Abcam, Cat. # ab87656) or IgG
(Sigma Aldrich) was processed for sequencing as described by Mortazavi et al61 with some
modifications. Double stranded cDNA was synthesized using the Just cDNA Double-
Stranded cDNA Synthesis Kit (Agilent Technology, Santa Clara, CA) according to the
manufacturer’s instructions. Illumina sequencing libraries were constructed from these
cDNA using a ChIP-Seq sample preparation kit (cat# IP-102-1001, Illumina, San Diego,
CA) with minor modifications. Illumina paired-end adaptor and PCR primers were used to
replace the single read adaptor and primers in the kit. Constructed libraries were subjected to
a final size-selection step on 10% Novex TBE gels (Invitrogen, Carlsbad). DNA fragments
of 175 – 200 bp were excised from a SYBR-green-stained gel. DNA was recovered from the
gel and quantified following Illumina’s qPCR quantification protocol. Paired end
sequencing of these libraries was then performed on an Illumina GA IIx to achieve 2×76 bp
reads. Paired-End reads were trimmed to 50 bp and aligned to the reference genome hg19
using BWA62 with the following parameters: bwa aln -o 1 -l 25 -k 2; bwa sampe -o 200. To
estimate a normalization factor (alpha) between the immunoprecipitations, the genome was
divided into course bins (10 Kb) and reads were counted for DNMT1 RIP and IgG control in
each bin. A linear regression was fitted across all non-zero bins and the slope of the
regression was used as a scaling factor (alpha) to normalize the RIP and control libraries. To
identify distinct regions specifically bound by DNMT1, all downstream analyses were
conducted on a set of regions derived by aggregating overlapping DNMT1 RIP reads into
contiguous intervals. Each DNMT1 interval was tested for significance by comparing the
number of reads within the interval the number of reads in the same region of the IgG
control, multiplied by the previously estimated scaling factor, alpha (exact binomial test,
P=0.5). Multiple tests were corrected by Benjamini-Hochberg. 16,186 intervals
(representing the start and end boundaries of contiguous, overlapping reads) were
determined to be significantly enriched in the DNMT1 RIP as compared to the IgG control
(P<0.0001; q<0.0001). A false discovery rate of 7.5% was determined by determining the
number of significantly enriched intervals in the IgG immunoprecipitate using DNMT1 as a
control. Significantly enriched DNMT1 intervals have a mean length of 347 bp and a
median of 67 reads per interval. Every peak represents an interval with a ‘height’ value: the
sum of all reads within an interval. All peaks were annotated with CEAS33 build on RefSeq
hg19. All DNMT1 RIP-Seq peaks were also annotated using the HOMER pipeline (version
4.2)34 which provide a comprehensive RNAs database (coding and non-coding, including
miRNA, snoRNA, rRNA, snRNA, tRNA, etc.).
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tA peak was considered belonging to a gene if located in the gene body or 3 kb up- or
downstream the gene (gene loci). Altogether, 6042 gene loci were covered by a least 1
significant RIPseq peak.
RNA Sequencing (RNAseq)
Total RNA was extracted with TRI Reagent® (MRC). RNA samples were treated with 10 U
of DNase I (Roche Applied Science) per 3 μg of total RNA at 37°C for one hour in the
presence of RNaseA inhibitor. Non-polyadenylated RNA fractions were selected with the
MicroPoly(A) Purist™ purification kit (Ambion). Total and non-polyadenylated RNA were
depleted of ribosomal RNA with Ribo-ZeroTM Magnetic Gold Kit (Epicentre). Double
stranded cDNA libraries were constructed using ScriptSeq™ v2 RNA-Seq Library
Preparation Kit (Epicentre) followed by Duplex Specific Nuclease (DSN) normalization
(Evrogen). DSN treated libraries were subjected to final size-selection in 3% agarose gel.
250–500 bp fragments were excised and recovered using the Qiaquick Gel Extraction Kit
(Qiagen). Libraries were sequenced (1/lane) on a Hi-Seq-2000 Illumina instrument. Raw
read sequences were deposited in GEO (Accession Number GSE32153). 2.96×108 reads
from the HL-60 and 3.75×108 76-bp paired end reads from the HL-60 polyA(+)-depleted
RNA were aligned to the human genome (hg) 19 (UCSC release) using Tophat263. Aligned
reads were assembled into individual full-length transcripts using Cufflinks v2.0.263 and a
merged assembly was created from the two assemblies and additionally, all level 1 and 2
transcripts from the gencode v11 catalog64 using cuffmerge36. To confirm the transcription
of the significant DNMT1 RIP-Seq peaks, we overlapped the peak intervals with the RIP-
Seq assemblies using the bedtools60 intersect Bed utility.
Reduced Representation Bisulfite Sequencing (RRBS)
RRBS was performed as described44. Briefly, high quality genomic DNA was isolated from
the myeloid cell line HL-60. DNA was digested with MspI (NEB), a methylation-insensitive
enzyme that cuts C’CGG. Digested DNA was size selected on a 4% NuSieve 3:1 Agarose
gel (Lonza). For each sample, two slices containing DNA fragments of 40–120 bp and 120–
220 bp, respectively, were excised from the unstained preparative portion of the gel. These
two size fractions were kept apart throughout the procedure and mixed 1:2 for the final
sequencing. Pre-annealed Illumina adaptors containing 5′-methyl-cytosine instead of
cytosine were ligated to size-selected MspI fragments. Adapter-ligated fragments were
bisulfite-treated using the EZ DNA Methylation kit (Zymo Research, Orange, CA). The
products were PCR amplified, size selected, and sequenced on the Illumina GAIIx at a
reading length of 36 bp. Sequencing reads were mapped to the reference genome hg19 using
RRBSmap45 allowing 2 mismatches. Reads from replicates were merged and processed as
previously described 46. We considered only CpG located in regions with a depth of
coverage greater than 3 reads. The β-score of CpG methylation in a given position is the
ratio of methylated CpGs within the total number of CpGs through all reads. The level of
gene methylation is the mean of all CpG β-scores within −2 kb from the TSS to the end of
first intron; for intronless genes, the entire gene body was considered. Genes with less than 3
sequenced CpG in the promoter or less than 3 sequenced CpG in the first exon-intron were
excluded.
For RRBS in R1 and UR overexpressing cells bisulfite sequenced UR -R1 genomes were
binned at 100 bp intervals using the R-Bioconductor/methylKit “tileMethylCounts” function
(http://code.google.com/p/methylkit)47. The level of differential methylation was computed
by comparing all sequenced CpG sites within the overlapping bins between the two samples
(R1 and UR). The significant differentially methylated bins were obtained using the Fisher
test from the R-Bioconductor/methylKit “calculateDiffMeth” function (qvalue < 0.01 and
methylation difference ≥50%). A gene was considered differentially methylated if the region
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tincluding the promoter (−2kb from the TSS) and 1st exon was overlapped by at least one
significant differentially methylated bins. In total, 11844 promoter/1st exon regions were
analyzed.
RNA Expression profiling
RNA isolated from HL-60 cells was employed for sample amplification and labeling using
the Whole Transcriptome assay reagent kits from Affymetrix. 10 μg of labeled RNA was
hybridized on Affymetrix GeneChip Human Gene 1.0 ST array. Hybridization, washing,
staining, and scanning were carried out as recommended by the manufacturer. Each
hybridization was performed in triplicate. Washes and staining were performed through the
Fluidics Station 400 and the GeneChip® Scanner 3000 (Affymetrix, Santa Clara, CA, USA)
was used to measure the fluorescence intensity emitted by the labeled target. Raw data
processing was performed using the Affymetrix GeneChip® Operating Software (GCOS).
Microarrays were RMA normalized using ‘affy’, an R-Bioconductor library65. CEBPA
expression was used as a threshold to define expressing (log2 score above 4) and not
expressing (log2 score below 4) genes for further analysis.
Gene Ontology and Pyknons comparison
GO analysis was performed with DAVID66. We focused our analysis on biological process
annotations. GO enrichment was scored using the Benjamini-Hochberg corrected p-value.
DNMT1 RIP-seq specific peaks were compared to the human pyknons database released in
January 2013 (https://cm.jefferson.edu/tools_and_downloads/pyknons.html).
Data integration
We used the RefSeq transcripts database built on hg19 (UCSC release) as a genome
annotation reference for Rip-Seq, RRBS, and microarray expression experiments. We
selected only the longest transcripts. Accordingly, the number of 40857 RefSeq Ids was
reduced to 23250 transcript Ids. Then, we annotated all RIP-Seq peaks against the gene loci
which include exonic, intronic, and UTR regions plus 3 kb upstream of the TSS and 3 kb
downstream of the Transcription End Site (TES) regions. We identified 6042 gene loci with
DNMT1-RIPseq peaks and 17208 gene loci without DNMT1-RIPseq peaks. Finally, we
focused our study on gene loci covered by the RRBS. We identified 4833 gene loci with
DNMT1-RIPseq peaks and covered by RRBS and 10973 gene loci without DNMT1-RIPseq
peaks and covered by RRBS. We plotted genes within each group against expression and
methylation profile. Using CEBPA levels of expression as a cut-off threshold, we defined
genes as “expressed” or “low or not expressed” if the log2 score was above or below 4,
respectively, and as “hypomethylated” and “methylated” genes with mean of all CpG scores
below and above 50%, respectively. We identified by this approach four clusters in each
group. In DNMT1 unbound group clusters: A (expressed, hypomethylated genes; 23.04%),
B (low or not expressed, methylated genes; 51.45%), E (expressed, methylated genes;
10.45%) and F (low or not expressed, hypomethylated genes; 15.06%). In DNMT1 bound
group clusters: C (expressed, hypomethylated genes; 56.64%), D (low or not expressed,
methylated genes; 12.04%), G (expressed, methylated genes; 12.08%), H (low or not
expressed, hypomethylated genes; 19.24%). In all RRBS covered group clusters: I
(expressed, hypomethylated genes; 33.32%), J (low or not expressed, methylated genes;
39.40%), K (expressed, methylated genes; 10.95%) and L (not or low expressed,
hypomethylated genes; 16.34%).
Statistical Analysis
Methylation changes of clones analyzed by bisulfite sequencing were calculated using the
Fisher’s exact test (GraphPad Prism Software Inc.). Methylation changes assessed by
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tMassARRAY were calculated using a student t-test (GraphPad Prism Software Inc.). The
statistical evaluation of DNMT1-RNA interaction versus expression and methylation was
estimated using the student t-test (box-plots; Supplementary Fig. 5d). The
overrepresentation of genes in clusters B and C following our hypothesis against those
which did not, was assessed using a 2-sample proportion test (Fig. 5b). P-values for t-test
and 2-sample proportion test, “t.test” and “prop.test”, respectively, were calculated by the R
functions (http://www.r-project.org). Values of P≤0.05 were considered statistically
significant. The mean ± s.d. of two or more replicates is reported.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Characterization of the ecCEBPA
a, Diagram of CEBPA transcripts; b, Assessment of transcripts by Northern blot
hybridization. c–e, Relative levels of the transcripts in cellular fractions. In panel d,
ecCEBPA levels are shown on different scales. qRT-PCR, bars indicate mean ± s.d. (n=3).
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tFigure 2. Loss- and gain-of-function studies demonstrate that ecCEBPA maintains CEBPA
expression by regulating methylation of the CEBPA locus
a, Diagram indicates: position of target sequences for shRNA constructs (sh1–3); the
fragment derived from the ecCEBPA employed for overexpression (R1) regions analyzed for
changes in DNA methylation (distal promoter; coding sequence, CDS; and 3′UTR); b–c,
The results of ecCEBPA loss-of-function in CEBPA-expressing U937 cells. Effect of
ecCEBPA-targeting shRNAs on CEBPA mRNA levels. qRT-PCR, bars indicate mean ± s.d.
(b) and methylation of the CEBPA promoter (c). DNA methylation changes are shown as the
ratios of methylated to unmethylated CpGs in all clones analyzed per each construct (n=14);
d–e, The results of ecCEBPA gain-of-function studies in K562 cells, in which CEBPA is
methylated and silenced. d, Effect of ecCEBPA upregulation on CEBPA mRNA levels. UR
= unrelated region. qRT-PCR, bars indicate mean ± s.d. (n=4); e, Effect of ecCEBPA
upregulation on methylation of the CEBPA locus (DNA methylation changes were assessed
as described in c; (n=14, for distal promoter; and n=6, for CDS, 3′UTR); f–g, The results of
transcription inhibition in U937 cells. f, ecCEBPA expression levels after treatment with
Actinomycin D and ML-60218 in synchronized and unsynchronized cells. qRT-PCR, bars
indicate mean ± s.d.; g, DNA methylation changes after treatment with Actinomycin D and
ML-60218 in synchronized (n=12) and unsynchronized (n=10) cells (assessed as described
in c). All bisulfite sequenced clones were analyzed by Fisher’s exact test. *P<0.05;
**P<0.01; ***P<0.001.
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tFigure 3. ecCEBPA–DNMT1 interactions; DNMT1 binds to RNA with greater affinity than to
DNA
a, Diagram showing position of qRT-PCR primers used in RIP, double-headed arrow; RNA
and DNA oligonucleotides used in EMSA and REMSA. Asterisks indicate position of
methylated cytosines; umDNA, hmDNA, and mDNA refer to unmethylated,
hemimethylated, and methylated DNA probes, respectively; b, ecCEBPA is
immunoprecipitated with anti-DNMT1 antibody. qRT-PCR, bars indicate mean ± s.d.; c,
RNA- DNMT1 binding is not affected by the absence of CpG dinucleotides (right panel).
Left and middle panels: RNA oligonucleotide R2 and its mutated form mut R2 (asterisks
indicate cytosines substituted into uridines), both able to form stem-loop-structures; d, RNA
oligonucleotide able to form stem-loop structure bind DNMT1 (R6); e, R5 RNA
oligonucleotide forming stem-loop structure (R5) has a greater DNMT1 affinity compared to
mut R5, unable to fold into stem-loop, (taken in equimolar amounts), at the same DNMT1
concentration; f, Left four panels: REMSA and EMSA performed with the fixed
concentration of ssRNA and dsDNA oligonucleotides (1 nM) and increasing concentrations
of DNMT1 protein; Right panel: Nonlinear regression analysis of bound RNA/DNA versus
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tDNMT1 concentrations. Error bars indicate s.d. from two independent experiments; g,
REMSA showing that RNA oligonucleotide R4, which is unable to form stem-loop
structure, displays lower DNMT1 affinity as compared to R5 (Fig. 3f left panel) at the same
DNMT1 concentrations; h, Left panel: Schematic diagram showing the DNMT1 domains
and the GST-DNMT1 isolated fragments (F1–F5); Right panel: GST-DNMT1 pull down
assay demonstrating binding of the folded RNA oligonucleotide R5 to the catalytic domain
of DNMT1.
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tFigure 4. Transcription impedes DNA methylation
a–d, Diagram showing the parallel in vitro transcription-methylation assays performed on a
hemimethylated template containing the T7 promoter (Supplementary Fig. 4) with and
without combinations of RNA polymerase, DNMT1, or both; e, DNMT1 exerts enzymatic
activity only in the absence of transcription. COBRA analysis of methylation patterns
acquired in reactions shown in b–d; f, DNA methylation changes as are shown as the ratios
of methylated to unmethylated CpGs in all clones analyzed per each construct (n=5). The
same effect was observed with two different RNA polymerases: T7 and Sigma-Saturated
(σ70)-Holoenzyme (E. coli RNA Polymerase). DNA methylation changes were analyzed by
Fisher’s exact test (*P<0.05; **P<0.01; ***P<0.001); g, in vitro DNMT1 assay
demonstrating DNMT1 enzymatic impairment by RNA oligonucleotides. The assay was
performed using ecCEBPA-related and unrelated RNA oligonucleotides. Sequences and
position of the ribooligonucleotides are shown on Fig. 3a and Supplementary Fig. 3. Error
bars indicate mean ± s.d. (n=2).
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tFigure 5. Genome-wide alignment of DNMT1 bound and unbound transcripts, DNA
methylation, and gene expression
a, Two-way Venn diagram showing DNMT1 specific peaks overlapping with transcribed
elements identified in HL-60 total and poly(A+)-depleted RNA-Seq libraries. b, Cloud plots
representing genes within DNMT1 unbound, bound and all RRBS-covered groups stratified
by DNA methylation and expression levels. All genes are presented in Supplementary Excel
File 2. c, Examples of genes from the C (CEBPA) and B (USP29) clusters. Peaks are
visualized using the SSIRs48. d, Model of DNMT1 sequestration. Upper panel: DNMT1 can
access transcriptionally inactive hemimethylated genomic regions. Lower panel: DNMT1
cannot access transcriptionally active hemimethylated genomic regions.
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